###begin article-title 0
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
SOD2 gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
A nonsynonymous coding variant in the manganese superoxide dismutase (SOD2) gene (V16A, ) has been implicated in neovascular age-related macular degeneration (AMD). However, the findings have been inconsistent. Two studies in Japanese populations reported an opposite direction of association of the same allele at the V16A variant, whereas one study in a Northern Irish population found no effect of the variant on the risk of developing neovascular AMD. To address these apparently contradictory reports, we validated the association in a Japanese population.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 510 514 510 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 128 131 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 159 171 <span type="species:ncbi:9606">participants</span>
###xml 225 228 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 229 241 <span type="species:ncbi:9606">participants</span>
In a Japanese population, we genotyped the V16A variant in 116 neovascular AMD patients, 140 polypoidal choroidal vasculopathy (PCV) patients, and 189 control participants. This association was also tested in a population of PCV participants to avoid variable findings across studies due to underlying sample heterogeneity and because disease phenotype was not well described in previous studies. We analyzed a tagging single nucleotide polymorphism (SNP) in addition to the V16A variant to capture all common SOD2 variations verified by the HapMap project. Genotyping was conducted using TaqMan technology. Associations were tested using single-SNP and haplotype analyses as well as a meta-analysis of the published literature. Population stratification was also evaluated in our study population.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 121 124 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
We found no detectable association of the V16A variant or any other common SOD2 variation with either neovascular AMD or PCV, as demonstrated by both single-SNP and haplotype analyses. Population structure analyses precluded stratification artifacts in our study cohort. A meta-analysis of the association between the V16A variant and neovascular AMD also failed to detect a significant association.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 142 145 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 252 257 <span type="species:ncbi:9606">human</span>
We found no evidence to support the role of any common SOD2 variations including the V16A variant in the susceptibility to neovascular AMD or PCV. Our study highlights the importance and difficulty in replicating genetic association studies of complex human diseases.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 500 501 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 447 450 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
Age-related macular degeneration (AMD) is a leading cause of blindness among elderly in developed nations [1]. AMD is a phenotypically heterogeneous disorder manifested at an early stage by large drusen and pigmentary abnormalities in retinal pigment epithelium (RPE). It progresses to an advanced stage by atrophy of the RPE and photoreceptors of the macula (geographic atrophy or dry AMD), or by the development of choroidal neovascularization (CNV) underneath the retina (neovascular or wet AMD) [2].
###end p 10
###begin p 11
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 259 260 259 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 630 631 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 672 673 672 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 35 38 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 213 216 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 254 257 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 422 425 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 508 516 <span type="species:ncbi:9606">patients</span>
Polypoidal choroidal vasculopathy (PCV) is a hemorrhagic and exudative macular disorder that is characterized by the development of vascular networks with terminal polypoidal lesions within the inner choroid [3]. PCV is proposed to be a specific type of CNV [3,4] and much debate exists as to whether they represent different entities with distinct etiology or neovascular subsets within a common etiologic pathway [5-7]. PCV occurs much more frequently in Asians than in Caucasians, accounting for 54.7% of patients with findings suggestive of neovascular AMD in the Japanese population [8], for 24.5% in the Chinese population [9], but for only about 10% in Caucasians [3].
###end p 11
###begin p 12
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 227 230 227 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 264 269 264 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARMS2</italic>
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 546 548 546 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
Numerous studies have presented evidence of a strong underlying genetic liability in AMD [10,11]. A total of four AMD risk loci have been identified with convincing statistical evidence, including the complement factor H gene (CFH) on chromosome 1q32 [12-17], the ARMS2/HTRA1 locus on 10q26 [18-23], the complement component 3 gene on 19p13 [24-28], and two neighboring genes on 6p21: complement factor B, and complement component 2 [29-32]. These four loci are associated with both types of advanced AMD: geographic atrophy and neovascular AMD [16,22,25,29].
###end p 12
###begin p 13
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 283 287 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
A large number of additional candidate susceptibility genes have been studied, but findings from most studies are inconclusive because of a lack of consistent replication [10,11]. Kimura et al. [33] reported that a nonsynonymous coding variant in the manganese superoxide dismutase (SOD2) gene (V16A, ) was significantly associated with neovascular AMD in a Japanese population. However, a subsequent study by Esfandiary et al. [34] on a Northern Irish population reported no effect of the V16A variant on the risk of developing neovascular AMD. A recent Japanese study by Gotoh et al. [35] was also unable to replicate the initially reported association; on the contrary, this group found a significant negative association of the same allele with neovascular AMD- I.E., this variant allele was significantly protective against neovascular AMD.
###end p 13
###begin p 14
###xml 279 283 279 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 998 999 998 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 1192 1194 1192 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 554 557 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 840 843 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 940 943 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
To address these apparently contradictory reports, the current study evaluated the association between the V16A variant and neovascular AMD in a Japanese population. We analyzed a tagging single nucleotide polymorphism (SNP) in addition to the V16A variant to capture all common SOD2 variations verified by the HapMap project [36]. Therefore, there was an increased coverage of this gene in our study as compared to the two previous studies in Japanese populations, which only examined the V16A variant [33,35]. We also tested for their association with PCV because the disease phenotype was not well described in previous studies [33,35]. Particularly, the initial study by the Japanese group did not consider the findings from indocyanine green (ICG) angiography in their evaluation [33], which is the only way to obtain a clear image of PCV lesions. This raises the possibility that their cohort may have included a measurable amount of PCV given its high prevalence in the Japanese population [8]. It has been suggested that attention to phenotype classification is a key aspect of genetic studies of AMD, to avoid variable findings across studies due to underlying sample heterogeneity [37]. Additionally, we performed a meta-analysis to assess the overall effect of the V16A variant on neovascular AMD across the different independent studies.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 6 18 <span type="species:ncbi:9606">participants</span>
Study participants
###end title 16
###begin p 17
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 1018 1020 1018 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 1088 1095 1088 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 218 230 <span type="species:ncbi:9606">participants</span>
###xml 253 265 <span type="species:ncbi:9606">participants</span>
###xml 422 434 <span type="species:ncbi:9606">participants</span>
###xml 574 577 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
###xml 730 733 <span type="species:ncbi:12143?0.0219256434699714">CNV</span>
###xml 737 740 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 754 766 <span type="species:ncbi:9606">participants</span>
###xml 801 813 <span type="species:ncbi:9606">participants</span>
This study was approved by the Institutional Review Board at Kobe University Graduate School of Medicine and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants. All case and control participants enrolled in this study were Japanese individuals recruited from the Department of Ophthalmology at Kobe University Hospital in Kobe, Japan. The majority of participants had participated in our previous studies [38,39] in which phenotyping criteria were fully described. In brief, all our neovascular AMD and PCV patients underwent comprehensive ophthalmic examinations including ICG angiography, and were defined as having angiographically well defined lesions of CNV or PCV. The control participants, who were not related to the case participants, were defined as individuals without macular degeneration and changes such as drusen or pigment abnormalities, and thus were categorized as having clinical age-related maculopathy staging system stage 1 [40]. The demographic details of our study population are presented in Table 1.
###end p 17
###begin title 18
Characteristics of the study population.
###end title 18
###begin p 19
###xml 55 58 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 76 88 <span type="species:ncbi:9606">participants</span>
###xml 291 294 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
A total of 116 subjects with neovascular AMD, 140 with PCV, and 189 control participants were enrolled in the present study. The gender breakdown, mean age, and age range of each population are shown. Abbreviations: age-related macular degeneration (AMD); polypoidal choroidal vasculopathy (PCV); standard deviation (SD).
###end p 19
###begin title 20
Marker selection
###end title 20
###begin p 21
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 250 251 250 251 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 466 470 466 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 511 512 511 512 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 613 617 613 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
To comprehensively and effectively cover common variations in the SOD2 locus, we ran the Tagger tool [41] from the HapMap project database [36] for the Japanese in Tokyo (JPT) population. The minor allele frequency (MAF) cutoff was set at 0.05; the r2 cutoff was set at 0.9; and the Tagger Pairwise mode was used. Two SNPs, the V16A variant () and , were selected for genotyping. On the basis of the HapMap JPT data, these two SNPs captured all seven HapMap SNPs in SOD2, with a MAF greater than 5% and a mean r2 value of 1.0. Therefore, this set of two SNPs is representative of the common genetic variations in SOD2 because it acts as a proxy marker for other untyped SNPs in this locus.
###end p 21
###begin title 22
SNP genotyping
###end title 22
###begin p 23
###xml 217 220 217 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174;</sup>
Genomic DNA was extracted from peripheral blood immediately after it was drawn using QIAamp DNA Blood Maxi Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Genotyping was conducted using TaqMan(R) SNP Genotyping Assays (Applied Biosystems, Foster City, CA) on a StepOnePlustrade mark Real-Time PCR system (Applied Biosystems), in accordance with the manufacturer's instructions.
###end p 23
###begin title 24
Statistical analysis
###end title 24
###begin p 25
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r42">42</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r43">43</xref>
###xml 415 416 413 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 692 694 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r44">44</xref>
###xml 981 983 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r45">45</xref>
###xml 309 312 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 325 337 <span type="species:ncbi:9606">participants</span>
Testing for association was performed using a software package  v1.00 [42]. Deviations from Hardy-Weinberg equilibrium were tested using the exact test [43] implemented in PLINK. The two SNPs reported in the present study did not show significant deviation from Hardy-Weinberg equilibrium in neovascular AMD, PCV, or control participants (all p>0.05). Single-marker association analyses were performed using the chi2-test or Fisher's exact test under allele (1 degree of freedom, df), genotypic (2 df), dominant (1 df), and recessive (1 df) genetic models. To adjust for differences in age and sex between case and control subjects, we performed logistic regression analyses using  software [44], assuming an additive genetic model by fitting age and sex as continuous and categorical covariates, respectively. A p>0.05 was considered statistically significant. Measures of linkage disequilibrium (LD) and haplotype association statistics were calculated using Haploview software [45]. Omnibus tests of haplotype associations were performed with .
###end p 25
###begin p 26
###xml 54 56 54 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r46">46</xref>
###xml 267 270 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Power calculations were conducted using  version 1.2 [46]. Assuming an additive genetic model, we had 80% power to detect an association of the V16A variant with an odds ratio (OR) >/=1.79 (or </=0.47) for the neovascular AMD sample, and >/=1.70 (or </=0.51) for the PCV sample.
###end p 26
###begin p 27
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r47">47</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r48">48</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r49">49</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r50">50</xref>
###xml 375 376 375 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 933 934 933 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 1038 1039 1038 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 1092 1094 1092 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pr</italic>
###xml 1096 1097 1096 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r51">51</xref>
Hidden population stratification in genetic association studies can generate a spurious positive or negative association [47]. To prevent potential stratification in our study cohort, population stratification was evaluated using STRUCTURE software [48] as described in previous studies [38,39,49,50]. The following 38 polymorphic SNPs, which are not in LD with each other (r2<0.04), were used for this analysis:  (1p13.2),  (1p21.3),  (1p36.12),  (1q32.1),  (2p23.1),  (2p24.1),  (2q35),  (3p26.2),  (3q25.32),  (4q13.3),  (5p15.1),  (6p11.2),  (7p22.1),  (7q22.1),  (8p12),  (9p21.3),  (9p24.3),  (9q33.1),  (10q11.22),  (10q24.2),  (11p15.5),  (11q24.3),  (12p13.2),  (12p13.33),  (12q13.3),  (13q12.11),  (14q13.2),  (14q32.13),  (15q22.31),  (16q24.3),  (17p13.2),  (17q23.1),  (18q11.2),  (19p13.2),  (19p13.3),  (20p11.21),  (21q21.1), and  (22q13.1). The log likelihood of each analysis with a varying number of populations (K) was computed from three independent runs (20,000 burn-in and 30,000 iterations). The best estimate of K was defined by calculating posterior probabilities (Pr, K=1, 2, 3, 4, or 5) based on the log likelihood, as described by Pritchard et al. [51].
###end p 27
###begin p 28
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r52">52</xref>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r53">53</xref>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r54">54</xref>
###xml 544 545 544 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 545 546 545 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r53">53</xref>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r54">54</xref>
###xml 584 585 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 585 586 585 586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 688 689 688 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 689 690 689 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 718 719 718 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 719 720 719 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 728 729 728 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q</italic>
###xml 733 734 733 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</italic>
###xml 740 741 740 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q</italic>
###xml 749 750 749 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q</italic>
###xml 796 797 796 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</italic>
###xml 828 829 828 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q</italic>
###xml 952 954 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r53">53</xref>
###xml 955 957 955 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r54">54</xref>
###xml 979 980 979 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 980 981 980 981 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1067 1069 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r55">55</xref>
A meta-analysis was performed using  and StatsDirect software (StatsDirect, Cheshire, UK). Data from our own study and two earlier case-control studies performed by Kimura et al. [33] and Gotoh et al. [35] were used for the meta-analysis. The study by Esfandiary et al. [34] was not included in the meta-analysis, because the allele and genotype data were unavailable. A summary OR was calculated using the random-effects model of DerSimonian and Laird [52]. Heterogeneity between studies was tested using Cochran's Q statistic [53,54] and the I2 statistic for inconsistency [53,54]. I2 is a measure of the proportion of total variation across studies due to heterogeneity beyond chance. I2 is provided by the formula I2=100% x Q - (k - 1)/Q, where Q is the Cochran's heterogeneity statistic and k is the number of studies. The Q-test is known to have poor power if there are few studies and is typically considered statistically significant at p<0.1 [53,54]. On the other hand, I2 is unaffected by the number of studies, and it is regarded as large for values >50% [55].
###end p 28
###begin title 29
Results
###end title 29
###begin p 30
###xml 163 167 163 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 204 208 204 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 276 277 276 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 377 384 377 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 520 527 520 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 474 477 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 703 706 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
We genotyped V16A () to validate the previously reported association and this SNP was supplemented by an additional SNP  to increase coverage of the variations in SOD2. These two SNPs captured all common SOD2 SNPs (MAF > 0.05) observed in the HapMap JPT subjects with a mean r2 of 1.0. The allele and genotype counts and results of single-SNP association analysis are given in Table 2. Neither of the two SNPs showed a significant association with either neovascular AMD or PCV in any of the genetic models (all p>0.05; Table 2). Adjustment for age and sex by logistic regression analyses under an additive model did not affect this conclusion (neovascular AMD, p=0.18 and 0.76 for  and , respectively; PCV, p=0.25 and 0.83 for  and , respectively).
###end p 30
###begin title 31
Allele and genotype distributions of  (V16A) and  and the results of association tests
###end title 31
###begin p 32
###xml 304 305 304 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 374 375 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</italic>
###xml 380 381 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 576 577 574 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 801 807 799 805 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">allele</sub>
###xml 88 91 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 989 992 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Neither of the two SNPs showed a significant association with either neovascular AMD or PCV in any of the genetic models. Alleles 1 and 2 represent major and minor alleles, respectively, and 11, 12, and 22 represent the homozygote of allele 1, heterozygote, and homozygote of allele 2, respectively. The T and C alleles of  are labeled as alleles 1 and 2, respectively. The G and A alleles of  are labeled as alleles 1 and 2, respectively. The genotypic, dominant, and recessive tests for  were performed using the Fisher's exact test, and the others were performed by the chi2-test. The dominant model compared a combination of heterozygotes and rare homozygotes to the common homozygotes. The recessive model compared the rare homozygotes to a combination of common homozygotes and heterozygotes. ORallele indicates per-allele odds ratio in the allelic test. Abbreviations: single nucleotide polymorphism (SNP); age-related macular degeneration (AMD); polypoidal choroidal vasculopathy (PCV); odds ratio (OR); confidence interval (CI); degree of freedom (df).
###end p 32
###begin p 33
###xml 240 247 240 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 279 286 279 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 252 255 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
The two SNPs genotyped were in moderate LD with each other (D =0.75) and haplotype association analyses were conducted using these two SNPs. No significant haplotype associations were found for either neovascular AMD (omnibus p=0.51, 3 df; Table 3) or PCV (omnibus p=0.80, 3 df; Table 3).
###end p 33
###begin title 34
Results of a haplotype-based association study
###end title 34
###begin p 35
###xml 114 115 114 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 149 150 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 346 349 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 442 445 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
*The alleles of single nucleotide polymorphisms forming haplotypes are presented (from left to right,  and ). The P values were calculated by the chi2-test on haplotype counts (1 degree of freedom [df]). Omnibus haplotype tests based on the four haplotypes were not significant (omnibus p=0.51, 3 df for neovascular AMD; omnibus p=0.80, 3 df for PCV). Abbreviations: age-related macular degeneration (AMD); polypoidal choroidal vasculopathy (PCV); odds ratio (OR); confidence interval (CI).
###end p 35
###begin p 36
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r48">48</xref>
###xml 161 163 161 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pr</italic>
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
Next, population stratification was evaluated by STRUCTURE [48] using 38 unlinked genome-wide SNPs. No evidence of stratification was found in our study cohort [Pr (K=1>0.99)] indicating that population stratification did not account for the results observed in the present study.
###end p 36
###begin p 37
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r52">52</xref>
###xml 422 430 422 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 481 482 481 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q</italic>
###xml 615 616 615 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 616 617 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 849 851 849 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 852 854 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 869 876 869 876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
Finally, a meta-analysis was performed to assess the association of the V16A variant with neovascular AMD across the different independent studies. Association results from our study (only neovascular AMD) and the two previous Japanese studies [33,35] were combined using the random-effects model of DerSimonian and Laird [52], and a summary OR for the model was calculated based on the allele frequency data. As shown in Figure 1, the heterogeneity test across studies (Cochran's Q statistic) was significant for this variant (p=0.0014), and inconsistency of the genetic effects across the three studies was high (I2=84.8%). No significant association was detected for the V16A variant, with a random-effects summary OR of 0.89 (95% CI, 0.47-1.67). Allele and genotype frequencies of the V16A variant observed in the two previous Japanese studies [33,35] are shown in Table 4.
###end p 37
###begin p 38
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r52">52</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r53">53</xref>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r54">54</xref>
###xml 496 497 496 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I</italic>
###xml 497 498 497 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r53">53</xref>
###xml 531 533 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r54">54</xref>
Meta-analysis of the V16A variant for its association with neovascular AMD. Odds ratios (ORs, black squares) and 95% confidence intervals (CIs, bars) are presented for each study. Also shown is the shaded diamond of the summary OR using the random-effects model of DerSimonian and Laird [52]. The genotype data included in the meta-analysis refer to the description of Kimura et al. [33] and Gotoh et al. [35]. Heterogeneity between studies was tested using Cochran's Q statistic [53,54] and the I2 statistic for inconsistency [53,54]. Abbreviations: AMD represents age-related macular degeneration.
###end p 38
###begin title 39
Allelic distributions of the V16A variant reported by earlier studies
###end title 39
###begin p 40
###xml 21 28 21 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
The genotype data in Table 3 refer to descriptions made by Kimura et al. [37] and Gotoh et al. [35]. Minor allele frequency of the V16A variant in case subjects were widely divergent; much higher frequency of the variant allele was observed in the Kimura et al.'s study.
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 324 328 324 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 410 414 410 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 670 674 670 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 466 469 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 582 585 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 716 719 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
To validate the previously described associations of the SOD2 V16A variant with neovascular AMD in Japanese populations [33,35], we examined this variant together with an additional SNP to increase coverage of the gene in an independent Japanese population with neovascular AMD. These two SNPs are perfect surrogates of all SOD2 SNPs identified by the HapMap project [36], and are representative of the common SOD2 variations. We also tested for an association with PCV, given the possibility that the study cohort in previous Japanese studies might have had a measurable amount of PCV [33,35]. We found no detectable association of the V16A variant or any other common SOD2 variation with either neovascular AMD or PCV by single-SNP or haplotype analysis. Population structure analyses precluded stratification artifact in our study cohort. A meta-analysis of the association between the V16A variant and neovascular AMD also failed to detect a significant association.
###end p 42
###begin p 43
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r56">56</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r56">56</xref>
###xml 242 246 242 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 399 403 399 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r57">57</xref>
###xml 989 991 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r57">57</xref>
SOD2 plays a crucial role in the detoxification of superoxide free radicals, which protects cells from reactive oxygen species-induced oxidative damage [56]. Oxidative stress is a hypothesized pathway for the pathophysiology of AMD [56], and SOD2 is a reasonable candidate gene for the disease. Kimura et al. [33] and Gotoh et al. [35] reported that opposite alleles at the same variant V16A in the SOD2 gene are positively associated with neovascular AMD in Japanese populations. This phenomenon, referred to as "flip-flop" associations, may serve as additional evidence of a true genetic association in populations of different ancestry (i.e., when noncausal variants are tested, observed effects of the variants can vary between studies because of differences in their correlation with other causative variants) [57]. Theoretically, flip-flop associations for a genuine causative variant would not occur in samples of the same ethnic origin and are often regarded as spurious findings [57].
###end p 43
###begin p 44
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 1226 1228 1226 1228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 1260 1262 1260 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 1372 1374 1372 1374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r58">58</xref>
###xml 1375 1377 1375 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r59">59</xref>
###xml 1410 1412 1410 1412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r60">60</xref>
###xml 1413 1415 1413 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r61">61</xref>
###xml 604 607 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 660 663 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 812 815 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
Minor allele frequencies of the V16A variant in control subjects were similar among the two earlier Japanese studies and our own study: 16.8% in the studies by Kimura et al. [33], 14.5% in Gotoh et al. [35], and 15.9% in the present study. However, minor allele frequencies of the V16A variant in case subjects were widely divergent; 24.7% in the studies by Kimura et al. [33], 9.1% in Gotoh et al. [35], and 12.1% in the present study. This inconsistency could possibly be due to differences in case selection criteria. Given the possibility that the original study might include a measurable number of PCV subjects, the potential role of the V16A variant in PCV was also explored in the present study. We found that the allele and genotype distributions of this variant were very similar between subjects with PCV and neovascular AMD, and the association results were consistent across these two phenotypes. Another possible reason for the much higher frequency of the V16A variant allele observed in the initial study is genotyping error. There are between-study differences in genotyping methods. The initial study used polymerase chain reaction restriction fragment length polymorphism analysis to genotype this variant [33], whereas we and Gotoh et al. [35] employed the TaqMan technology, which is now a well established technology for genotyping the V16A variant [58,59]. As shown in previous studies [60,61], different genotyping technologies can yield inconsistent genotyping results.
###end p 44
###begin p 45
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 380 384 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
SOD2 maps to chromosome 6q25.3, a region that has not been implicated in AMD by any genome-wide scans [10]. To further validate its association, we accessed the NEI/NCBI  database, which provides results of genome-wide association study on 395 individuals with AMD and 198 controls from the National Eye Institute Age-Related Eye Disease Study (AREDS). This study looked at three SOD2 SNPs, including the V16A variant and two other SNPs ( and ), and found no significant association (all nominal p>0.1), confirming our findings and those of Esfandiary et al. [34].
###end p 45
###begin p 46
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD2</italic>
###xml 156 159 <span type="species:ncbi:46221?0.06469298245614036|species:ncbi:28355?0.01644736842105263|species:ncbi:158372?0.003289473684210526">PCV</span>
###xml 266 271 <span type="species:ncbi:9606">human</span>
In conclusion, we found no evidence to support the role of any common SOD2 variation including the V16A variant in the susceptibility to neovascular AMD or PCV. Our study highlights the importance and difficulty in replicating genetic association studies of complex human diseases. The only way to have complete confidence in genetic association is by conducting independent replications. Further replications will allow a definitive conclusion regarding the etiological relevance of this variant in AMD.
###end p 46
###begin title 47
Acknowledgments
###end title 47
###begin p 48
This study was supported by a Grant-in-Aid (C) 17591836 from the Ministry of Education, Science, and Culture, Tokyo, Japan. The authors have no financial or conflicting interests to disclose.
###end p 48
###begin title 49
References
###end title 49
###begin article-title 50
Prevalence of age-related macular degeneration in the United States.
###end article-title 50
###begin article-title 51
Age-related macular degeneration.
###end article-title 51
###begin article-title 52
Polypoidal choroidal vasculopathy.
###end article-title 52
###begin article-title 53
Classification and diagnostic criteria of age-related macular degeneration.
###end article-title 53
###begin article-title 54
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration.
###end article-title 54
###begin article-title 55
Clinicopathologic findings in polypoidal choroidal vasculopathy.
###end article-title 55
###begin article-title 56
The origins of polypoidal choroidal vasculopathy.
###end article-title 56
###begin article-title 57
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of exudative age-related macular degeneration in Japanese patients.
###end article-title 57
###begin article-title 58
###xml 75 83 <span type="species:ncbi:9606">patients</span>
Subtype lesions of neovascular age-related macular degeneration in Chinese patients.
###end article-title 58
###begin article-title 59
The genetics of age-related macular degeneration: a review of progress to date.
###end article-title 59
###begin article-title 60
An update on the genetics of age-related macular degeneration.
###end article-title 60
###begin article-title 61
Complement factor H polymorphism and age-related macular degeneration.
###end article-title 61
###begin article-title 62
Complement factor H variant increases the risk of age-related macular degeneration.
###end article-title 62
###begin article-title 63
Complement factor H polymorphism in age-related macular degeneration.
###end article-title 63
###begin article-title 64
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration.
###end article-title 64
###begin article-title 65
CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD.
###end article-title 65
###begin article-title 66
Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration.
###end article-title 66
###begin article-title 67
Susceptibility genes for age-related maculopathy on chromosome 10q26.
###end article-title 67
###begin article-title 68
Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk.
###end article-title 68
###begin article-title 69
HTRA1 promoter polymorphism in wet age-related macular degeneration.
###end article-title 69
###begin article-title 70
A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration.
###end article-title 70
###begin article-title 71
HTRA1 variant confers similar risks to geographic atrophy and neovascular age-related macular degeneration.
###end article-title 71
###begin article-title 72
Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA.
###end article-title 72
###begin article-title 73
Complement C3 variant and the risk of age-related macular degeneration.
###end article-title 73
###begin article-title 74
Variation in complement factor 3 is associated with risk of age-related macular degeneration.
###end article-title 74
###begin article-title 75
C3 R102G polymorphism increases risk of age-related macular degeneration.
###end article-title 75
###begin article-title 76
Complement component C3 and risk of age-related macular degeneration.
###end article-title 76
###begin article-title 77
Complement Component 3 (C3) Haplotypes and risk of advanced age-related macular degeneration.
###end article-title 77
###begin article-title 78
AMD Genetics Clinical Study Group, Hageman GS, Dean M, Allikmets R. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration.
###end article-title 78
###begin article-title 79
Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration.
###end article-title 79
###begin article-title 80
Analysis of rare variants in the complement component 2 (C2) and factor B (BF) genes refine association for age-related macular degeneration (AMD).
###end article-title 80
###begin article-title 81
Further assessment of the complement component 2 and factor B region associated with age-related macular degeneration.
###end article-title 81
###begin article-title 82
Genetic association of manganese superoxide dismutase with exudative age-related macular degeneration.
###end article-title 82
###begin article-title 83
Association study of detoxification genes in age related macular degeneration.
###end article-title 83
###begin article-title 84
Manganese superoxide dismutase gene (SOD2) polymorphism and exudative age-related macular degeneration in the Japanese population.
###end article-title 84
###begin article-title 85
Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits.
###end article-title 85
###begin article-title 86
Role of RDBP and SKIV2L variants in the major histocompatibility complex class III region in polypoidal choroidal vasculopathy etiology.
###end article-title 86
###begin article-title 87
Coding variant Met72Thr in the PEDF gene and risk of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
###end article-title 87
###begin article-title 88
Evaluation of the clinical age-related maculopathy staging system.
###end article-title 88
###begin article-title 89
Efficiency and power in genetic association studies.
###end article-title 89
###begin article-title 90
PLINK: a tool set for whole-genome association and population-based linkage analyses.
###end article-title 90
###begin article-title 91
A note on exact tests of Hardy-Weinberg equilibrium.
###end article-title 91
###begin article-title 92
SNPStats: a web tool for the analysis of association studies.
###end article-title 92
###begin article-title 93
Haploview: analysis and visualization of LD and haplotype maps.
###end article-title 93
###begin article-title 94
Sample size requirements for matched case-control studies of gene-environment interaction.
###end article-title 94
###begin article-title 95
###xml 15 20 <span type="species:ncbi:9606">human</span>
The effects of human population structure on large genetic association studies.
###end article-title 95
###begin article-title 96
Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies.
###end article-title 96
###begin article-title 97
A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction.
###end article-title 97
###begin article-title 98
Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia.
###end article-title 98
###begin article-title 99
Inference of population structure using multilocus genotype data.
###end article-title 99
###begin article-title 100
Meta-analysis in clinical trials.
###end article-title 100
###begin article-title 101
Heterogeneity in meta-analyses of genome-wide association investigations.
###end article-title 101
###begin article-title 102
Measuring inconsistency in meta-analyses.
###end article-title 102
###begin article-title 103
Quantifying heterogeneity in a meta-analysis.
###end article-title 103
###begin article-title 104
The role of oxidative stress in the pathogenesis of age-related macular degeneration.
###end article-title 104
###begin article-title 105
No gene is an island: the flip-flop phenomenon.
###end article-title 105
###begin article-title 106
SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes.
###end article-title 106
###begin article-title 107
A common coding variant in CASP8 is associated with breast cancer risk.
###end article-title 107
###begin article-title 108
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Lack of association with the CD28/CTLA4/ICOS gene region among Norwegian multiple sclerosis patients.
###end article-title 108
###begin article-title 109
No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.
###end article-title 109

